Member Info for peterobert

Earlier this week, the innovative work being done with Steriwave at the Mid Yorkshire Teaching NHS Trust was the focus of a BBC news article. This coverage offers a moment to acknowledge the commitment and expertise of the teams at Pontefract and Pinderfields hospitals, whose contributions are at the heart of these advancements.

It is a privilege to see our collaborative efforts in enhancing surgical safety and tackling antimicrobial resistance being recognized. The article delves into the details of this initiative and its significance, and I believe you'll find it both informative and reflective of the strides we're making together.

Simple Solutions

to Prevent Complex Infections

https://ondinebio.com/investors/reports-documentation/

Https://ondinebio.com/media/steriwave-prevents-sinonasal-ssis/?portfolioCats=68

Good News is worth repeating my friend !!!

Earlier today, we announced further important inroads into the UK market alongside a deepening of our HCA relationship.

HCA Healthcare UK has approved Steriwave for use in its healthcare facilities, leveraging the positive experience and study findings from Professor Claire Hopkins, Professor of Rhinology at King's College London and Consultant ENT Surgeon at Guy's & St Thomas' NHS Foundation Trust. Professor Hopkins was the first to use presurgical nasal photodisinfection prior to sinus surgeries and demonstrated significant reductions in post-surgical infections and antibiotic use--a particular advantage in this patient population. You can see here speaking about her Steriwave experience and study findings here.

We are very pleased as this procurement authorization facilitates the ability for HCA clinicians across the HCA UK network to adopt Steriwave to prevent healthcare-associated infections for their patients and reduce unnecessary antibiotic use. HCA UK has built a world-class network of over 30 facilities in London and Manchester, with its latest venture opened in Birmingham in 2023. HCA is the largest private healthcare provider in the world and one of the leading private healthcare providers in the UK. HCA Healthcare UK, is the only private hospital group in the UK to have the highest level of critical care beds in all of its facilities, and it positively takes on new challenges in innovation and advancing critical care. We believe our clinical work to advance the use of Steriwave into ICUs will be leveraged by this key procurement relationship in due course.

The procurement clearance at HCA UK, following the recent news of our first NHS hospital deployments in Mid Yorkshire, we believe bodes well for our growth goals.

For more details, please read

RBC target 60p

Targe 60p

Https://www.londonstockexchange.com/news-article/OBI/entry-into-icu-market-expands-revenue-potential/16406786

Https://www.londonstockexchange.com/news-article/OBI/entry-into-icu-market-expands-revenue-potential/16406786

We hope that you have seen today's news release in which we announced that we are accelerating our efforts to expand into the Intensive Care Units (ICU) market due to growing interest from hospitals. The ICU market substantially increases our target market and, more importantly, we believe, can accelerate hospital adoption given the infection problem in all ICUs. Expanding use within our current hospitals can be a significant growth factor as well as improving time to new hospital adoption.

We need to be in the ICU—patients in ICUs are at high risk for healthcare-acquired infections (HAI) due to the high prevalence of invasive procedures and devices. ICUs are where the most vulnerable and immunocompromised patients are found. Because nasal decolonization has been shown to reduce ICU infection rates in other studies, we believe that our broad-spectrum Steriwave® can really make a difference reducing the infection rates—and therefore the mortality rates.

One in every eight ICU patients in Canada suffers from infections not related to their original illness and acquired in the hospital when their immune systems are down. Mortality rates are highest in the ICU as a result. With ICU mortality rates at 9% in North America and up to 18% in Europe, we need to be saving more lives sooner. So, we have made the decision to accelerate our ICU clinical pilot work and look forward to updating you in the quarters ahead on this progress.

You might miss out

just my opinion - always research first

Chief Executive Officer Carolyn Cross commented: "We have long known that the ICU is an epicenter of hospital infection due to the vulnerable population of critically ill patients and the high use of invasive procedures including intubation, catheters and ports. We believe that Steriwave can offer a far more effective solution to ICU infections than nasal antibiotics, and we are looking forward to capitalising on this large market segment. Ondine will be able to reach ICUs using its existing sales and marketing infrastructure, making this an obvious area for us to expand into."

Just last month, Ondine reported significant commercial progress to date in 2024, ahead of its expectations, with its Steriwave technology deploying in eight new healthcare facilities, including six new hospitals. This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago.

By Sabrina Penty, Alliance News reporter

8.56-8.94

Given spare funds

I would buy more

at these prices

Https://www.statista.com/statistics/1197095/clinical-trial-cost-per-patient-by-therapy-area/

Operating results for the first half year were in line with management expectations despite a challenging economic backdrop and unfavorable stock markets which contributed to the deferral of 2023 fundraising plans. The Company has made solid progress toward its two key 2023 corporate objectives:

· Preparing for the upcoming Phase 3 clinical study-a critical component for US market approval of the Company's nasal photodisinfection. ( Steriwave)

· Advancing commercial efforts and geographic footprint into the Canadian, British, Spanish, and Mexican markets.

Financial highlights

· Loss from operations in H1 2023 of $8.03 million (H1 2022:

Steriwave® is a broad-spectrum antimicrobial providing targeted decolonization safely, effectively, quickly.

Broad-spectrum: Kills all pathogens (bacterial, viral, fungal).

Non-resistance forming.

Safe and painless treatment for patients within 5 minutes.

High compliance, clinician administered.

Suitable for repetitive use (e.g. healthcare workers, frequent hospital visitors, long-term care facilities, outpatients, dialysis patients).

Should be out soon

Https://www.bing.com/alink/link?url=https%3a%2f%2fwww.ondinebio.com%2f&source=serp-local&h=1T2gSvZnlMZ5Bzq0tiWcaQF3IxkpHArQFgPYbjRnQ3A%3d&p=lw_gb&ig=1DFD1AC5F21A479AA114301168FB90A5&ypid=YN1144x262737905

Matt Ross joined Proactive's Stephen Gunnion after the company sealed its first commercial deal with an NHS trust, starting with the Pontefract and Pinderfields hospitals. This follows a successful 500-patient elective hip and knee surgical quality initiative at Pontefract, leading to its adoption across the two hospitals.

The company aims to develop a business case with York health economics group and Mid Yorkshire for broader NHS adoption, based on the successful outcomes and health economics work.

Ross also highlighted Ondine's commercial momentum, including the deployment of Steriwave in eight new healthcare facilities and a growing international presence, now spanning 22 facilities in Canada and expanding in the UK and Spain.

The success is attributed partly to Steriwave's effectiveness in reducing the need for antibiotics, as demonstrated in a UK study, and its alignment with antimicrobial resistance efforts. Ondine plans to continue expanding in European markets, capitalize on its success in Canada, and explore potential in the United States through FDA phase three trials.

William (Bill) Kanz has been appointed as Senior Vice President, Engineering and Operations. In this role, Mr. Kanz will lead the engineering, operations and manufacturing teams, supporting Ondine's rapid commercial growth. Mr. Kanz is a certified quality engineer and lean six-sigma black belt, and brings a wealth of product management, manufacturing, and product development expertise to the company. Building on his operational management capabilities, he has developed some of the world's leading atherectomy devices, ultrasound catheters and blood pumps, and has 47 patents to his name.

Caetano Sabino, Ph.D. has been appointed as Ondine's Director of Research and Development, building on his extensive pharmaceutical sciences background and many years of development of light-activated therapeutics. Dr. Sabino is an expert in photodynamic disinfection, and has authored numerous important publications, textbooks, and patents in the field. He most recently held the position of CEO, BioLambda, Científica e Comercial LTDA, Sao Paulo, Brazil manufacturing industrial equipment for light-based disinfection in hospitals, clinics, and the food industry.

Carolyn Cross, CEO, Ondine Biomedical commented. "We will be providing an update on our upcoming dual priorities of continued significant commercial expansion and initiation of Phase 3 clinical trial in the USA with our partner, HCA Healthcare."